We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Biogen Inc | NASDAQ:BIIB | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
6.04 | 2.98% | 208.50 | 208.50 | 209.65 | 210.83 | 199.10 | 201.22 | 1,894,099 | 01:00:00 |
By Kosaku Narioka
Eisai Co. shares were indicated sharply higher Wednesday morning after the Japanese drug maker and Biogen Inc. said their experimental Alzheimer's disease drug significantly slowed progression of the disease in a large study.
The shares were indicated 17% higher at Y6,784 ($46.85). No trades have taken place because buy orders overwhelmed sell orders even at the upper-end of the day's trading range.
Eisai and Biogen said Wednesday that their drug, lecanemab, reduced cognitive and functional decline by 27%, compared with a placebo, over 18 months in a Phase 3 study of 1,800 patients with early-stage Alzheimer's.
The late-stage study had been eagerly anticipated by researchers and investors after the failed launch of Aduhelm, which was also developed by Eisai and Biogen.
Last year, Aduhelm became the first new Alzheimer's treatment approved by the U.S. Food and Drug Administration in nearly two decades. But the drug's commercial prospects were doomed by a Medicare decision in April to refuse routine coverage of it.
The Topix subindex for pharmaceutical companies was recently down 0.2%, while the Nikkei Stock Average was 1.0% lower.
Write to Kosaku Narioka at kosaku.narioka@wsj.com
(END) Dow Jones Newswires
September 27, 2022 21:50 ET (01:50 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Biogen Chart |
1 Month Biogen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions